Zevra Therapeutics, INC Form 4 insider transactions

Tamara A. Favorito, a Director at Zevra Therapeutics, Inc., has been granted 30,000 stock options as compensation for her board service.

Zevra Therapeutics, Inc. reports the grant of stock options to Director Alicia Secor as compensation for her board service.

Corey Michael Watton, a Director at Zevra Therapeutics, Inc., was granted 30,000 stock options as compensation for his board service.

Douglas W. Calder, a Director at Zevra Therapeutics, Inc., was granted 30,000 stock options as compensation for his board service.

Zevra Therapeutics, Inc. reports the grant of 30,000 stock options to Director Thomas Anderson as compensation for board service.

Rahsaan Thompson, Chief Legal & Compliance Officer at Zevra Therapeutics, Inc., reported a transaction involving the acquisition of 1,794 shares of common stock.

Zevra Therapeutics Director John B. Bode exercised stock options, acquiring 78,400 shares of common stock.

Zevra Therapeutics' CFO, Justin Renz, was granted 300,000 stock options with an exercise price of $9.55, vesting over four years.

Zevra Therapeutics CEO Neil F. McFarlane sold 14,625 shares of common stock following the vesting of 37,500 restricted stock units.

ZEVRA Therapeutics SVP of Finance and Corporate Controller, Timothy J. Sangiovanni, sold 3,000 shares of common stock for $9.1827 per share under a pre-arranged 10b5-1 plan.

Zevra Therapeutics' Chief Commercial Officer, Joshua Schafer, sold 10,500 shares of common stock for approximately $96,499.25 under a pre-arranged 10b5-1 plan.

ZEVRA Therapeutics SVP of Finance, Timothy J. Sangiovanni, reported the vesting and subsequent sale of company common stock.

Rahsaan Thompson, Zevra Therapeutics' Chief Legal & Compliance Secretary, reported the sale of common stock and the grant and vesting of restricted stock units and stock options.

ZEVRA THERAPEUTICS' Chief Medical Officer, Adrian W. Quartel, reported new equity grants and a sale of common stock.

Zevra Therapeutics' Chief Commercial Officer, Joshua Schafer, reported the acquisition of new equity awards and the sale of common stock under a pre-arranged 10b5-1 plan.

ZEVRA Therapeutics CEO Neil F. McFarlane reported recent stock sales and new equity grants, including restricted stock units and stock options.

Former Zevra Therapeutics CFO LaDuane Clifton reported the vesting and subsequent tax-related disposition of company stock following his departure on December 31, 2025.

Zevra Therapeutics Director Alicia Secor was granted 45,000 stock options with an exercise price of $8.17, vesting over three years or upon a change in control.

Zevra Therapeutics CEO Neil F. McFarlane reported a planned acquisition of 50,000 shares via RSU vesting and a subsequent sale of 19,500 shares at $10.8158, both scheduled for October 10, 2025, under a 10b5-1 plan.

ZEVRA Therapeutics Director Tamara A. Favorito acquired 3,175 shares of common stock at $7.7852 per share.

Zevra Therapeutics Director Alvin Shih acquired 20,000 shares of common stock at a weighted average price of $7.89, signaling increased insider ownership.

Zevra Therapeutics Director John B. Bode acquired 5,000 shares of common stock for $9.165 each, increasing his total beneficial ownership to 45,000 shares.

Rahsaan Thompson, Chief Legal & Compliance Secretary of Zevra Therapeutics, Inc., sold 24,000 shares of common stock for approximately $9.21 per share under a Rule 10b5-1 plan.

Rahsaan Thompson, Chief Legal & Compliance Secretary of Zevra Therapeutics, Inc., has exercised 66,666 restricted stock units, converting them into common stock, with 133,334 units remaining to vest.

Zevra Therapeutics, Inc. Director Alvin Shih was granted 30,000 stock options with an exercise price of $8.62 as part of his compensation for board service.

Zevra Therapeutics, Inc. director Wendy L. Dixon was granted 30,000 stock options with an exercise price of $8.62 as part of her compensation for board service, vesting over the next year or upon specific events.

Zevra Therapeutics, Inc. director Douglas W. Calder was granted 30,000 stock options as compensation for his board service, aligning his interests with shareholders.

Tamara A. Favorito, a Director at Zevra Therapeutics, Inc., was granted 30,000 stock options with an exercise price of $8.62 as part of her compensation for board service.

Corey Michael Watton, a Director at Zevra Therapeutics, Inc., was granted 30,000 stock options with an exercise price of $8.62 as part of his compensation for board service.

Zevra Therapeutics, Inc. director John B. Bode was granted 30,000 stock options with an exercise price of $8.62 as part of his compensation for board service, vesting over the next year or upon specific events.